Coronavirus: Thread

[grarpamp]

They were afraid to enable their first gen tool to really kill.

The next weaponized global population reducer will be
much more dangerous, hundreds of millions will die,
more than any mass death by any cause ever before.

As always, prepare and protect yourself, or not,
however you wish, and leave others the fuck alone.

Meanwhile the entire criminal COVID-19 operation,
cover-up, and narrative continues to be exposed on all
fronts...


COVID Vaccines Show 24 Times More Adverse Reactions Than Others

https://www.theepochtimes.com/health/covid-vaccines-show-24-times-more-adverse-reactions-than-other-vaccines-5423426

https://www.health.wa.gov.au/~/media/Corp/Documents/Health-for/Immunisation/Western-Australia-Vaccine-Safety-Surveillance-Annual-Report-2021.pdf

Authored by Jessie Zhang via The Epoch Times

An Australian report on adverse reactions to vaccines has revealed
that COVID-19 vaccinations had 24 times the rate of adverse reactions
in compared to all other vaccines. (Alberto Pizzoli/AFP via Getty
Images)

The latest report on adverse reactions to vaccines in Western
Australia has revealed that COVID-19 vaccinations have 24 times the
rate of adverse reactions in the state compared to all other vaccines.

According to the state’s vaccine safety surveillance report (pdf),
COVID-19 vaccines showed that for every 100,000 COVID-19 vaccines
administered, 264 adverse events following immunisations (AEFIs) were
recorded.

For all other vaccinations, 11.1 AEFIs were recorded, making the
COVID-19 vaccines 23.8 times more likely than non-COVID-19 vaccines to
result in adverse events.
Table showing numbers of vaccines administered and adverse events
reported, with rate of adverse events, for non-COVID-19 vaccines and
COVID-19 vaccines, 2021. (Image from the Department of Health in
Western Australia)

The rate of adverse events varied among different types of COVID-19 vaccines.

The Spikevax (Moderna) vaccine recorded 281.4 AEFIs per 100,000 doses,
Comirnaty (Pfizer) recorded 244.8, and the Vaxzevria (AstraZeneca)
vaccine, which was removed from the vaccine program after reports
emerged of blood clotting in younger people, recorded 306.

Adverse events following vaccination can range from mild, such as a
sore arm, to serious conditions, such as anaphylaxis, thrombosis with
thrombocytopaenia syndrome (TTS), Guillain-Barré syndrome (GBS),
myocarditis, and pericarditis.
Collaboration Continues With 3-in-1 Super Jab

Meanwhile, despite these concerns, the Australian government’s
partnership with Moderna to produce vaccines using experimental
messenger RNA technology to prepare for the next pandemic means these
vaccines are here to stay.

The company has been forming a trifecta jab to address the main
respiratory viruses—influenza, COVID-19, and RSV to maintain its
market share amid the falling revenue of vaccine companies as the
health crisis subsides.

Moderna’s COVID-19 vaccine sales of US$18.4 billion in 2022 are
expected to dive to $5 billion this year.

Recently, it was granted expedited approval by Australia’s authority
for medicines for its mRNA-1345 (RSV vaccine), meaning that the
company will be able to launch the vaccines in Australia before any
other country in the world.
Registered nurse Emma Ahearn administers the Pfizer COVID-19 vaccine
to Millie Persic sitting on the lap of mother Maria Persic in Sydney,
Australia, on Jan. 11, 2022. (Jenny Evans/Getty Images)

A spokesperson from Australia’s Therapeutic Goods Administration told
the Epoch Times that Moderna was granted an accelerated approval
process on March 30 after satisfying all of the following criteria:

    the medicine is new
    the medicine is for the treatment, prevention, or diagnosis of a
life-threatening condition
    no other medicines that are intended to treat, prevent or diagnose
the condition are included in the Australian drug register or there is
substantial evidence that this medicine provides a significant
improvement in efficacy or safety of the treatment, prevention or
diagnosis of the condition compared to those goods already included in
the register
    there is substantial evidence that the medicine provides a major
therapeutic advance.

However, phase 3 clinical trials for Moderna’s mRNA version of the
seasonal influenza vaccine have been underwhelming, showing a high
rate of side effects.

Although the vaccine generates a strong immune response against the A
strains of the flu, its efficacy against B strains is not better than
existing approved vaccines.

Additionally, 70 percent of trial participants who received the shot
reported adverse reactions such as headaches, swelling, and fatigue
compared to 48 percent for the conventional flu vaccine.